Our research focuses on these two important features of lipid metabolism changes and high expression of HIF-2α in renal cancer, investigating the intersection of these processes, we aim to expand the understanding of HIF-2α-mediated lipid reprogramming and develop new strategies for the treatment of ccRCC. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.